Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BMEA 
Biomea Fusion Inc (BMEA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: BMEA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.83
1 Year Target Price $7.83
| 4 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.54% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.08M USD | Price to earnings Ratio - | 1Y Target Price 7.83 |
Price to earnings Ratio - | 1Y Target Price 7.83 | ||
Volume (30-day avg) 9 | Beta -0.14 | 52 Weeks Range 1.29 - 12.85 | Updated Date 10/15/2025 |
52 Weeks Range 1.29 - 12.85 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -68.73% | Return on Equity (TTM) -170.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 77583143 | Price to Sales(TTM) - |
Enterprise Value 77583143 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.75 | Shares Outstanding 70703639 | Shares Floating 49243894 |
Shares Outstanding 70703639 | Shares Floating 49243894 | ||
Percent Insiders 7.97 | Percent Institutions 41.54 |
Upturn AI SWOT
Biomea Fusion Inc
Company Overview
History and Background
Biomea Fusion, Inc. is a biopharmaceutical company focused on discovering and developing novel covalent small molecules to treat genetically defined cancers and metabolic diseases. Founded in 2018, it has focused on developing irreversible inhibitors targeting specific proteins.
Core Business Areas
- Drug Discovery and Development: Focuses on developing covalent small molecules that irreversibly bind to and inhibit target proteins implicated in diseases like cancer and diabetes.
Leadership and Structure
The leadership team includes individuals with experience in drug discovery and development, including the CEO and Chief Scientific Officer. The company has a typical biopharmaceutical organizational structure with departments focused on research, development, clinical trials, and operations.
Top Products and Market Share
Key Offerings
- BMS-986126: An investigational covalent menin inhibitor being developed for type 2 diabetes. Currently in Phase 1 trials. Competitors include those pursuing other diabetes therapies like GLP-1 receptor agonists (Novo Nordisk, Eli Lilly).
- Other preclinical programs: Biomea has several earlier-stage discovery programs in oncology, targeting specific cancer-driving proteins. Competitors are other cancer therapeutic companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and subject to regulatory oversight, technological advancements, and evolving healthcare needs. Covalent drug discovery is an area of increasing interest.
Positioning
Biomea Fusion is positioned as an innovator in covalent drug discovery, focusing on developing targeted therapies for unmet medical needs. Their competitive advantage lies in their expertise in developing covalent inhibitors.
Total Addressable Market (TAM)
The TAM for diabetes and cancer therapies is very large, worth hundreds of billions of dollars annually. Biomea is positioned to capture a portion of this TAM if their therapies are successful in clinical trials and gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel covalent drug discovery platform
- Experienced leadership team
- Focus on genetically defined diseases
- Strong intellectual property portfolio
Weaknesses
- Early-stage pipeline
- Limited clinical data
- Dependence on successful clinical trials
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new disease areas
- Advancement of clinical programs into later stages
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from other drug developers
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- NVO
Competitive Landscape
Biomea Fusion is a small player compared to established pharmaceutical giants. Their advantage lies in their novel covalent drug discovery platform, but they face significant competition in the diabetes and oncology markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of their preclinical and clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates are subject to change based on clinical data.
Recent Initiatives: Recent initiatives include advancing BMS-986126 into Phase 1 trials.
Summary
Biomea Fusion is a high-risk, high-reward biopharmaceutical company focused on a novel drug discovery approach. While their technology holds promise, they are in early stages of development. Successful clinical trials and partnerships are crucial for their future success, but they face strong competition and the risks associated with drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Company website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies carries significant risk, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomea Fusion Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2021-04-16 | Interim CEO & Director Dr. Michael J. M. Hitchcock Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | Website https://biomeafusion.com |
Full time employees 63 | Website https://biomeafusion.com | ||
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.